Jaafar Bennouna
Overview
Explore the profile of Jaafar Bennouna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
12055
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mourlanette J, Rousseau-Bussac G, Mallah S, Guisier F, Zalcman G, Veillon R, et al.
Target Oncol
. 2025 Mar;
PMID: 40080277
Background: ROS1 chromosomic rearrangement is a rare oncogenic driver, and patients with this rearrangement benefit from specific targeted treatments in the first-line setting. However, therapeutic options are limited in pretreated...
2.
Herbreteau G, Marcq M, Sauzay C, Carpentier M, Pierre-Noel E, Pons-Tostivint E, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075630
: Circulating tumor DNA (ctDNA) analysis is a powerful tool for non-invasive monitoring of tumor burden and treatment response. Reliable quantification methods are critical for the effective use of ctDNA...
3.
Taieb J, Souglakos J, Boukovinas I, Falcoz A, Pages F, Messaritakis I, et al.
J Clin Oncol
. 2025 Feb;
:JCO2400648.
PMID: 39903903
Purpose: Immunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving prognostication and tailoring adjuvant treatments in patients resected from a stage III colon cancer (CC). Here,...
4.
Lucibello F, Gounant V, Aldea M, Duruisseaux M, Perol M, Chouaid C, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100743.
PMID: 39850629
Introduction: Pralsetinib is a RET inhibitor found to have antitumor activity in advanced, metastatic, fusion-positive NSCLC. Objective: To assess real-world efficacy of pralsetinib and treatment sequences in patients with RET...
5.
Pilati C, Soulabaille A, Gallois C, Blons H, Cayre A, Sroussi M, et al.
Gastroenterology
. 2024 Nov;
PMID: 39612956
Background & Aims: ERBB2 pathway activation, through amplification or activating mutations, represents a new target for colon cancer (CC) treatment. Molecular methods were compared with the gold standard for assessing...
6.
Andre T, Elez E, Van Cutsem E, Jensen L, Bennouna J, Mendez G, et al.
N Engl J Med
. 2024 Nov;
391(21):2014-2026.
PMID: 39602630
Background: Patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard chemotherapy with or without targeted therapies. Nivolumab plus ipilimumab has shown clinical benefit in...
7.
Stoekle H, Beuzeboc P, Payet T, Herve C, Bennouna J
Eur J Clin Invest
. 2024 Sep;
54(12):e14315.
PMID: 39235135
No abstract available.
8.
Pons-Tostivint E, Ezzedine R, Goronflot T, Crequit P, Chatellier T, Raimbourg J, et al.
Lung Cancer
. 2024 Jul;
194:107887.
PMID: 38991282
Introduction: Chemotherapy combined with immunotherapy (CT-IO) is the standard treatment for patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC). This study evaluates the effectiveness of second-line (2L) following CT-IO. Patients...
9.
Sun J, Adenis A, Enzinger P, Shah M, Kato K, Bennouna J, et al.
Future Oncol
. 2024 May;
20(35):2709-2721.
PMID: 38695479
Treatment options for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) are improving. Current guidelines recommend first-line pembrolizumab plus chemotherapy for patients with unresectable or metastatic ESCC, which...
10.
Hulo P, Deshayes S, Fresquet J, Chene A, Blandin S, Boisgerault N, et al.
Respir Res
. 2024 Apr;
25(1):156.
PMID: 38581044
Background: Lung cancers represent the main cause of cancer related-death worldwide. Recently, immunotherapy alone or in combination with chemotherapy has deeply impacted the therapeutic care leading to an improved overall...